OSR Health, Inc. (OSRHW) EBITDA (2022 - 2026)

OSR Health (OSRHW) has 5 years of EBITDA data on file, last reported at -$3.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 25.68% year-over-year to -$3.7 million; the trailing twelve-month figure through Mar 2026 stood at -$19.1 million (down 68.82% YoY), and the FY2025 full-year result was -$18.3 million, down 56.85% from the prior year.
• EBITDA rose to -$3.7 million in Q1 2026, from -$6.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $530029.0 in Q2 2023 to a low of -$6.4 million in Q4 2025.
• A 5-year average of -$2.0 million and a median of -$2.3 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 53746.66% in 2023 and plunged 2465.27% in 2024, its largest moves.
• Tracing OSRHW's EBITDA over 5 years: stood at -$14252.0 in 2022, then jumped by 3064.09% to $422442.0 in 2023, then slumped by 481.31% to -$1.6 million in 2024, then tumbled by 296.41% to -$6.4 million in 2025, then surged by 42.57% to -$3.7 million in 2026.
• Business Quant data shows OSRHW's EBITDA at -$3.7 million in Q1 2026, -$6.4 million in Q4 2025, and -$3.8 million in Q3 2025.